After T2DM mice were treated with epimedin C in the present work, FBG, HOMA-IR, and oral glucose tolerance significantly decreased, while the hepatic glycogen and insulin contents remarkably increased. The gene discussed is INS; the disease is type 2 diabetes mellitus.